Related Experiment Video

Updated: Apr 16, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

961

Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in

Alba Fabiola Torres1, Cleto Nogueira1, Juliana Magalhaes1

  • 1Department of Investigative Pathology, Argos Laboratories, 60175-047 Fortaleza, CE, Brazil.

Analytical Cellular Pathology (Amsterdam)
|March 13, 2015
PubMed

Insights

This study found that Epidermal Growth Factor Receptor (EGFR) expression varies by lung adenocarcinoma subtype and stage. Understanding these protein expressions may improve targeted therapies and predict drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pathology

Background:

  • Targeted therapies for Epidermal Growth Factor Receptor (EGFR) are vital for tumors with specific molecular alterations.
  • Heterogeneity in long-term response to EGFR-targeted therapies necessitates further investigation into underlying mechanisms.
  • Understanding tumor biology, including protein expression patterns, is crucial for optimizing cancer treatment.

Purpose of the Study:

  • To analyze the protein expression of EGFR and downstream signaling molecules (STAT3, Akt, ERK1/2) in lung adenocarcinoma.
  • To correlate these protein expressions with clinicopathological variables and histological subtypes.
  • To explore the relationship between EGFR pathway activation and tumor characteristics, potentially impacting oncogenesis and drug resistance.

Main Methods:

  • Retrospective analysis of protein expression using immunohistochemistry in 96 resected lung adenocarcinoma cases.
  • Assessment of EGFR, STAT3, phospho-Akt, and phospho-Erk1/2 protein levels.
  • Correlation of protein expression with clinicopathological data, including tumor stage and histological subtype.

Main Results:

  • Higher EGFR expression was observed in tumors with vascular invasion, higher stage, and solid/cribriform histology compared to lepidic subtypes.
  • EGFR was significantly overexpressed in solid tumors versus lepidic tumors.
  • Acinar predominant tumors showed the highest rate of ERK1/2 positivity (19%).
  • Strong correlations were found between ERCC1 positivity and STAT3, Akt, and ERK1/ERK2.
  • Downstream molecule expression did not directly correlate with EGFR expression, suggesting alternative pathway activation.

Conclusions:

  • Protein expression patterns of EGFR and its downstream effectors differ across lung adenocarcinoma subtypes and stages.
  • The observed heterogeneity in pathway activation may contribute to tumor development and resistance to EGFR-targeted therapies.
  • Integrating protein expression data with the new lung adenocarcinoma classification can enhance understanding of tumor-specific pathways and inform treatment strategies.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K